Boston University Medical Center Hematology and Medical Oncology

Topics

• Multiple Myeloma Research and Treatments 464
• Hemoglobinopathies and Related Disorders 428
• Amyloidosis: Diagnosis, Treatment, Outcomes 304
• Lung Cancer Treatments and Mutations 154
• Chronic Lymphocytic Leukemia Research 108
• Blood Coagulation and Thrombosis Mechanisms 105
• Hematopoietic Stem Cell Transplantation 102
• Acute Myeloid Leukemia Research 90
• Venous Thromboembolism Diagnosis and Management 86
• Cancer Immunotherapy and Biomarkers 72
• Cancer Genomics and Diagnostics 66
• Hemophilia Treatment and Research 48

Most cited

1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

   The New England journal of medicine · 2021 · 2,130 citations · Nikhil Munshi, Fabio Petrocca

2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

   Lancet (London, England) · 2021 · 1,514 citations · Nikhil Munshi

3. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

   The New England journal of medicine · 2021 · 1,440 citations · Martin Steinberg

4. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.

   Journal of the American College of Cardiology · 2023 · 520 citations · Vaishali Sanchorawala

5. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

   The New England journal of medicine · 2023 · 550 citations · Yvonne Efebera

6. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.